Antineoplastics

Antineoplastics Reactions 1680, p38 - 2 Dec 2017 Acute hepatitis B infection: case report A 58-year-old woman developed acute hepatitis B infection following treatment with cyclophosphamide, doxorubicin, prednisone and vincristine [routes, dosages and outcome not stated]. The woman, who was diagnosed with diffuse large B-cell lymphoma, presented to the hospital with 1-week history of asthenia, nausea, vomiting and abnormal liver function. During admission, her serology was positive for hepatitis-B surface antigen (HBsAg) and hepatitis-B e antigen (HBeAg) and was negative for hepatitis-B surface antibody (HBsAb), antibodies of hepatitis-C virus, hepatitis-A virus, hepatitis-E virus and HIV. Her serum blood hepatitis-B virus (HBV) DNA concentration was 2.05 x 10 copies/mL. The limit of detection by PCR was 500 copies/mL. Her total bilirubin (TBIL), ALT and AST levels were 38.4 µmol/L (normal: 0 19.1 µmol/L), 581 U/L – – (normal: 0 45 U/L), 324 U/L (normal: 0 37 U/L), respectively. She was diagnosed with an acute hepatitis-B based on the typical clinical results and her past history. The woman was treated with entecavir and radix glycyrrhizae agent. After 4 weeks’ therapy, the HBV-DNA concentration fell below detectable levels and her serum AST and AST levels returned to almost normal limits. Six weeks after starting the entecavir therapy, she presented E-antigen serological conversion. Her HBsAg disappeared after 9 weeks. After 12 weeks of the treatment, her HBsAb was tested positive. Subsequently, the entecavir therapy was discontinued. Subsequent investigations revealed that, 8 years ago, she had been vaccinated against hepatitis-B and had consistent records of HBsAb positive. About 8 weeks before the hospitalisation, she had latest test for HBsAb when she was preparing to receive tumour chemotherapy. The precise titer was 78.6 IU/L. Nearly 4 months earlier, she was diagnosed with diffuse large B-cell lymphoma and received the CHOP regimen which consisted of cyclophosphamide, vincristine, doxorubicin and prednisone. Substantial side effects of chemotherapy included hair loss, anorexia, and decreased platelets and leukocyte counts. About 4 weeks after the chemotherapy completion, the symptomatic hepatitis-B virus infection appeared. Based on her medical history and the incubation period of the hepatitis-B virus infection, it was assumed that, she possibly acquired the infection during the chemotherapy or in a very short time after it. About 5 weeks before she developed obvious acute hepatitis related symptoms, she was transfused with 1 platelet unit (blood transfusion) for improvement of thrombocytopenia. Subsequent donor investigations revealed that, the donor was asymptomatic acute HBV infected person and woman’s CHOP chemotherapy weakened her immune system and enhanced the body sensitivities leading to development of acute hepatitis B infection. Author comment: "The case reported here demonstrated that tumor chemotherapy with the CHOP regimen might have weakened the immune system of this lymphoma patient and enhanced the body sensitivities to hepatitis B virus, then led to the infection, though she had a reliable record of HBsAb positive." "Substantial side effects included hair loss, anorexia, and decreased platelets and leukocytes." Kang FB, et al. Hepatitis B virus infection in an HBsAb-positive lymphoma patient who received chemotherapy: A case report. Medicine 96: e8518, No. 44, Nov 2017. Available from: URL: http://doi.org/10.1097/MD.0000000000008518 - China 803285333 0114-9954/17/1680-0001/$14.95 Adis © 2017 Springer International Publishing AG. All rights reserved Reactions 2 Dec 2017 No. 1680 http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Reactions Weekly Springer Journals

Antineoplastics

Reactions Weekly , Volume 1680 (1) – Dec 2, 2017
Free
1 page

Loading next page...
1 Page
 
/lp/springer_journal/antineoplastics-QISYpvJxM5
Publisher
Springer International Publishing
Copyright
Copyright © 2017 by Springer International Publishing AG, part of Springer Nature
Subject
Medicine & Public Health; Drug Safety and Pharmacovigilance; Pharmacology/Toxicology
ISSN
0114-9954
eISSN
1179-2051
D.O.I.
10.1007/s40278-017-38969-3
Publisher site
See Article on Publisher Site

References

You’re reading a free preview. Subscribe to read the entire article.


DeepDyve is your
personal research library

It’s your single place to instantly
discover and read the research
that matters to you.

Enjoy affordable access to
over 12 million articles from more than
10,000 peer-reviewed journals.

All for just $49/month

Explore the DeepDyve Library

Unlimited reading

Read as many articles as you need. Full articles with original layout, charts and figures. Read online, from anywhere.

Stay up to date

Keep up with your field with Personalized Recommendations and Follow Journals to get automatic updates.

Organize your research

It’s easy to organize your research with our built-in tools.

Your journals are on DeepDyve

Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.

All the latest content is available, no embargo periods.

See the journals in your area

Monthly Plan

  • Read unlimited articles
  • Personalized recommendations
  • No expiration
  • Print 20 pages per month
  • 20% off on PDF purchases
  • Organize your research
  • Get updates on your journals and topic searches

$49/month

Start Free Trial

14-day Free Trial

Best Deal — 39% off

Annual Plan

  • All the features of the Professional Plan, but for 39% off!
  • Billed annually
  • No expiration
  • For the normal price of 10 articles elsewhere, you get one full year of unlimited access to articles.

$588

$360/year

billed annually
Start Free Trial

14-day Free Trial